ACCELERATOR PRODUCTION OF CU 64 FOR PET AND RADIOTHERAPY

这个项目的目标是开发一个自动化系统，用于 利用小型生物医用材料生产高比活度铜 加速器。铜-(Tau 1/2=12.7hr)是一位中年老人 发射正电子的放射性核素是一种有用的正电子示踪剂 发射断层扫描(PET)以及一种有前途的放射治疗药物 癌症的治疗。铜-目前是反应堆生产的，而且， 因为它只能在少数反应堆设施中生产， 它的可用性极其有限。 一期试验表明，铜的高产-- 具有高比活度和放化纯度的产品可通过 ~(64)Ni(p，n)~(64)Cu在常规PET回旋加速器或低回旋加速器上的反应 能量直线加速器。在第二阶段，自动目标和 将为生产和生产开发放化处理系统 铜的提纯.，成像所需的量和 放射治疗。 该系统的使用将允许使用正电子发射计算机断层扫描诊断 不能用短命的人研究的生理条件 发射正电子的放射性核素并将使其广泛使用成为可能 铜标记的治疗剂。铜的漫长半衰期--将 还允许将治疗剂和显像剂分发到站点 不具备同位素生产能力的公司。 拟议的商业应用：铜-生产系统 在这个项目中开发的将立即引起研究人员的兴趣 能够接触到小型生物医学回旋加速器和现有的回旋加速器- 以放射性药物为基础的设施。现场64Cus的供应情况 生产系统将在中国的发展中发挥重要作用 使用铜标记化合物的成像和放射治疗方案。

The goal of this project is to develop an automated system for the production of high specific activity copper-64 using small biomedical accelerators. Copper-64 (Tau 1/2=12.7 hr) is an intermediate-lived positron-emitting radionuclide which is a useful radiotracer for positron emission tomography (PET) as well as a promising radiotherapy agent for the treatment of cancer. Copper-64 is currently reactor produced, and, because it can only be produced at a small number of reactor facilities, its availability is extremely limited. Experiments conducted in Phase I showed that high yields of copper-64 with high specific activity and radiochemical purity can be produced via the 64Ni(p,n)64Cu reaction using conventional PET cyclotrons or low energy linear accelerators. In Phase II, an automated target and radiochemical processing system will be developed for the production and purification of copper-64 in the quantities required for imaging and radiotherapy. The availability of this system will allow the use of PET to diagnose physiological conditions which cannot be studied with the short-lived positron-emitting radionuclides and will make possible the widespread use of Cu-labeled therapeutic agents. The long half-life of copper-64 will also allow the distribution of therapeutic and imaging agents to sites that do not have isotope production capabilities. PROPOSED COMMERCIAL APPLICATION: The copper-64 production system developed in this program will be of immediate interest to researchers having access to small biomedical cyclotrons and to existing cyclotron- based radiopharmacy facilities. The availability of an on-site 64Cu production system will play an important role in the development of imaging and radiotherapy protocols using copper-labeled compounds.